Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Pasithea Therapeutics Corp.KTTA · Entity 7685 | Member of 10% owner group | October 17, 2022 | October 19, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Pasithea Therapeutics Corp.
Report date October 17, 2022 · Filed October 19, 2022
Jointly reported with Delaney David, Elderhill Corp
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 227,521 |
Reported balance
After 2022-10-17 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2022-10-17 · Purchase · Acquired 1,000 · Balance 227,521 F1: The shares were purchased by Elderhill Corporation, of which David Delaney serves as sole director and President. F2: 191,321 shares are held by Concord IP2, Ltd., of which David Delaney serves as sole director and President, and 36,200 shares are held by Elderhill Corporation. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were purchased by Elderhill Corporation, of which David Delaney serves as sole director and President.
F2: 191,321 shares are held by Concord IP2, Ltd., of which David Delaney serves as sole director and President, and 36,200 shares are held by Elderhill Corporation.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 17, 2022 Filed Oct 19, 2022 21:29 UTC | Pasithea Therapeutics Corp. KTTA · Entity 7685 | PurchaseCommon Stock | 1,000 | $1.11 | $1,110.00 |
DisclosureSEC source: 0001209191-22-054100 · doc4.xml · nonDerivative · entry 1 Delaney David · CIK 0001943013 · Member of 10% owner group Concord IP2 Ltd. · CIK 0001943018 · Member of 10% owner group Elderhill Corp · CIK 0001943046 · Member of 10% owner group Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 227,521 F1 · shares: The shares were purchased by Elderhill Corporation, of which David Delaney serves as sole director and President. F2 · ownership.nature: 191,321 shares are held by Concord IP2, Ltd., of which David Delaney serves as sole director and President, and 36,200 shares are held by Elderhill Corporation. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.